Nanobiotix (NANO) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Key product and clinical development updates

• NBTXR3, a hafnium oxide nanoparticle, enhances radiotherapy efficacy and is tumor-agnostic, with potential to improve outcomes or reduce toxicity for millions of patients receiving radiation.

• Phase III NANORAY-312 targets frail, elderly head and neck cancer patients ineligible for cisplatin, with 500 patients randomized; primary endpoint is PFS, key secondary is OS.

• Study 102 showed 82% overall response and 63% complete response, with median survival of 42 months in responders.

• Study 1100 in metastatic head and neck cancer, combining NBTXR3 with anti-PD-1, showed 48% response in PD-1 naive patients; further survival data expected with longer follow-up.

• MD Anderson collaboration is advancing studies in pancreatic, lung, and esophageal cancers, with updates expected soon.

Strategic partnerships and commercialization

• Global co-development and commercialization agreement with Janssen (J&J) in 2023 accelerated development and expanded resources.

• Ongoing transfer of phase III trial sponsorship to J&J to expedite registration and market entry, aiming for interim readout in H1 2026.

• J&J is also sponsoring a phase II trial in stage III lung cancer, with trial design and enrollment updates expected soon.

• Financial terms include significant clinical, regulatory, and sales milestones, with royalties in the low teens to low twenties.

Financial and operational outlook

• Cash runway extends into Q3 2025, with disciplined capital allocation and further updates expected with mid-year results.

• Collaboration with J&J provides validation and enables exploration of new platforms beyond NBTXR3.